Intellectual Property India Publishes Patent Application for 'Prodrugs Of 4'-Substituted Nucleoside Reverse Transcriptase Inhibitors' Filed by Merck Sharp & Dohme Llc

MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517079406 A) filed by Merck Sharp & Dohme Llc, Rahway, U.S.A., on Aug. 21, for 'prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors.'

Inventor(s) include Embrey, Mark W.; Layton, Mark E; Raheem, Izzat T.; and Grobler, Jay A.

The application for the patent was published on Sept. 12, under issue no. 37/2025.

According to the abstract released by the Intellectual Property India: "The present invention is directed to prodrugs of compound A: which are nucleoside reverse transcriptase translocation inhibitors (NRTTI) and are useful in the inhibition of HIV reverse transcriptase. The present invention also relates to the use of these compounds for prophylaxis of infection by HIV, treatment of infection by HIV, and prophylaxis, treatment, and delay in the onset or progression of AIDS and/or AIDS-related complexes."

The patent application was internationally filed on Jan. 26, 2024, under International application No.PCT/US2024/013021.

Disclaimer: Curated by HT Syndication.